Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, and Small Pharma Inc. (TSX.V: DMT) (OTCQB: DMTTF), a U.K.-based biotechnology company focused on short-duration psychedelic therapies for mental health conditions, today announced their entry into a definitive arrangement agreement. Under … Continue reading InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Acquisition That Will Create ‘Clear Market Leader in Novel Psychedelic Therapeutics’